AbbVie (ABBV) Asset Writedowns and Impairment (2018 - 2024)

AbbVie (ABBV) has reported Asset Writedowns and Impairment for 4 consecutive years, with $4.5 billion the latest figure, recorded in Q4 2024.

• In Q4 2024, Asset Writedowns and Impairment rose 218.58% year-over-year to $4.5 billion; the TTM figure through Dec 2025 stood at $4.5 billion (changed 0.0% YoY), while the FY2025 annual figure was $847.0 million, down 81.08% from the prior year.
• Asset Writedowns and Impairment rose to $4.5 billion in Q4 2024 per ABBV's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $4.5 billion in Q4 2024 and bottomed at $80.0 million in Q2 2023.
• Historically, Asset Writedowns and Impairment has averaged $1.6 billion across 3 years, with a median of $1.1 billion in 2022.
• Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 174.55% — and 2024, when it jumped 218.58%.
• AbbVie's Asset Writedowns and Impairment stood at $770.0 million in 2022, then soared by 82.47% to $1.4 billion in 2023, then surged by 218.58% to $4.5 billion in 2024.
• Business Quant data shows ABBV's Asset Writedowns and Impairment at $4.5 billion in Q4 2024, $1.4 billion in Q4 2023, and $2.1 billion in Q3 2023.